| Recognized for its role in helping promising startups grow by combining private investment capabilities with public support
| Organically connecting investment, R&D, and global expansion… Providing close support for the commercialization and market settlement of promising deep-tech companies
| Synergy in matching private investment with government R&D… Serving as a bridge for technology-intensive startups to enter the global market
JNPMEDI Partners (CEO Kwon-ho Jung), a global pharmaceutical and bio accelerator, announced on the 9th that it has been selected as an operator for the Ministry of SMEs and Startups’ ‘Scale-up TIPS’ and as a professional institution for the Korea Health Industry Development Institute’s ‘Professional Investment Institution-Linked Investment Attraction Support Program’.
Both programs are designed to help technology-based startups grow by combining private investment capabilities with public support. This selection is drawing attention as it once again proves the investment expertise and execution capabilities of JNPMEDI Partners.
‘Scale-up TIPS’ is a program where private investment firms select promising deep-tech companies and execute a pre-investment of more than 1 billion KRW. When the investment firm exercises its recommendation right for the company, the government provides R&D funds for 3 to 4 years to the selected companies after evaluation. Since its launch in December 2021, a total of 557 companies have been selected and received 333.8 billion KRW in support. Among them, 214 companies have attracted follow-up investments worth approximately 1.255 trillion KRW, and 13 companies have successfully entered the stock market.
Through this selection, JNPMEDI Partners has secured the right to recommend promising deep-tech companies and will promote the linkage of R&D funds for selected companies based on a pre-investment of more than 1 billion KRW per company. Furthermore, it plans to provide close support throughout the entire process—from commercialization strategy establishment to global expansion—by utilizing its cooperation network with universities, research institutes, and clinical sites.
At the same time, as a professional institution for the ‘Professional Investment Institution-Linked Investment Attraction Support Program,’ JNPMEDI Partners will also support the investment attraction of bio-health startups. Based on the insights and networks accumulated in the bio-health industry, it will play the role of a close coach to drive substantial funding for matched companies. The plan is to select about six bio-health companies to operate customized growth programs, focusing on creating practical results through IR strategy establishment tailored to each company's stage and technical characteristics, global market research, and investor consulting. The primary goal is to achieve investment attraction for three or more companies.
Jae-hyun Lee, Vice President of JNPMEDI Partners, stated, “This selection is a result of recognition for JNPMEDI Partners’ integrated growth support model, which connects investment, R&D, commercialization, and global expansion into a single flow.” He added, “We will strengthen execution-oriented support so that promising deep-tech and bio-health companies can move beyond the technical stage and lead to market results.”
| Recognized for its role in helping promising startups grow by combining private investment capabilities with public support
| Organically connecting investment, R&D, and global expansion… Providing close support for the commercialization and market settlement of promising deep-tech companies
| Synergy in matching private investment with government R&D… Serving as a bridge for technology-intensive startups to enter the global market
JNPMEDI Partners (CEO Kwon-ho Jung), a global pharmaceutical and bio accelerator, announced on the 9th that it has been selected as an operator for the Ministry of SMEs and Startups’ ‘Scale-up TIPS’ and as a professional institution for the Korea Health Industry Development Institute’s ‘Professional Investment Institution-Linked Investment Attraction Support Program’.
Both programs are designed to help technology-based startups grow by combining private investment capabilities with public support. This selection is drawing attention as it once again proves the investment expertise and execution capabilities of JNPMEDI Partners.
‘Scale-up TIPS’ is a program where private investment firms select promising deep-tech companies and execute a pre-investment of more than 1 billion KRW. When the investment firm exercises its recommendation right for the company, the government provides R&D funds for 3 to 4 years to the selected companies after evaluation. Since its launch in December 2021, a total of 557 companies have been selected and received 333.8 billion KRW in support. Among them, 214 companies have attracted follow-up investments worth approximately 1.255 trillion KRW, and 13 companies have successfully entered the stock market.
Through this selection, JNPMEDI Partners has secured the right to recommend promising deep-tech companies and will promote the linkage of R&D funds for selected companies based on a pre-investment of more than 1 billion KRW per company. Furthermore, it plans to provide close support throughout the entire process—from commercialization strategy establishment to global expansion—by utilizing its cooperation network with universities, research institutes, and clinical sites.
At the same time, as a professional institution for the ‘Professional Investment Institution-Linked Investment Attraction Support Program,’ JNPMEDI Partners will also support the investment attraction of bio-health startups. Based on the insights and networks accumulated in the bio-health industry, it will play the role of a close coach to drive substantial funding for matched companies. The plan is to select about six bio-health companies to operate customized growth programs, focusing on creating practical results through IR strategy establishment tailored to each company's stage and technical characteristics, global market research, and investor consulting. The primary goal is to achieve investment attraction for three or more companies.
Jae-hyun Lee, Vice President of JNPMEDI Partners, stated, “This selection is a result of recognition for JNPMEDI Partners’ integrated growth support model, which connects investment, R&D, commercialization, and global expansion into a single flow.” He added, “We will strengthen execution-oriented support so that promising deep-tech and bio-health companies can move beyond the technical stage and lead to market results.”